wfcadmin

Sugar Substitute Linked to Heart, Thrombotic Risk Metabolomic studies have linked the low calorie sweetener xylitol to increased cardiovascular and thrombotic risk by 57-80% higher after adjustment for variables. Xylitol is a sugar alcohol found naturally in strawberries, spinach, cauliflower, but it is commercially made from corncobs, birch trees or genetically engineered bacteria. It is […]

A More Selective Enoxaparin Thromboprophylaxis Protocol May Be Safer for New Moms Treating postpartum women using a selective risk-stratified approach was linked to reduced rates of wound hematomas from delivery to 6 weeks post partum (0,.3% vs. 0.7%) without increasing the rate of VTE (0.008% vs 0.0014%). A retrospective observational study was conducted on 17,000

FDA Approves Additional Indication for Fibryga® for Fibrinogen Supplementation in Bleeding Patients with Acquired Fibrinogen Deficiency, Potentially Ushering in a New Standard of Care Fibryga, a fibrinogen replacement factor to be used in patients with acquired fibrinogen deficiency has received expanded approval from the FDA. It is a rapid and more precise treatment for severe

Clot Removal Device Correction: Inari Medical Updates Use Instructions for ClotTriever XL Catheter due to Reports of Patient Injury and Death from Device Entrapment and Pulmonary Emboli This recall involves updating instructions for using the ClotTriever XL, 30mm device, and does not involve removing them from where they are used or sold. The ClotTriever XL Catheter is used

Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors A prophylactic treatment, marstacimab (Hympavzi), was approved by the FDA to reduce or prevent bleeding episodes in hemophilia A and B patients over the age of 12 that did not have inhibitors. It works by targeting the Kunitz 2 domain of tissue factor pathway

Heart Attack Patients Who Receive Heparin ASAP Are Better Primed for Cath Lab It has been determined that patients who are pretreated with a loading dose of unfractionated heparin as early as possible had a better likelihood of Thrombolysis in Myocardial Infarction (TIMI) flow grade 3 of the infarct-related artery at diagnostic angiography before primary

Eltrombopag Improves Outcomes in Kids With Newly Diagnosed ITP ITP is a rare bleeding disorder that affects 5-10/100,000 children annually. Many of the patients experience spontaneous remission within 6-12 months of diagnosis. Some require treatment for bleeding and impact on quality of life. Eltrombopag is a small molecule non-peptide thrombopoietin receptor agonist. The PINES trial

Lupus Patients See More Vascular Risk, but It’s Modifiable In a prospective study in Greece, 95 SLE patients and patients age 71 age and sex matched with healthy individuals were followed for 10 years. All participants were white and 90% were women. Median bp for patients was 116/71 mm Hg for patients and 120/76 mm

New accreditation POC requirements for coagulation testing The POC checklist for coagulation now include requirements for specimen collection and handling. POC testing is being used more frequently and best practices should be utilized. This is a challenging task even for core laboratories. There are three new requirements. Specimen handling for Whole Blood Testing requires that specimens

Anti-Factor XI Anticoagulants: Breakthrough or Bust? The OCEANIC- AF phase 3 trial failed to demonstrate efficacy of the anti- XI peptide asundexian revealing a fourfold risk of ischemia when compared with DOACs. leading cardiologists to question if they will be widely used in the prevention of ischemic risk. Otamixaban was also rejected because of unsatisfactory